The leading CEO forum for pharmaceutical producers, distributors and retailers in Russia

11 - 12 November 2020

Corinthia Saint-Petersburg Hotel

Speaker confirmations in 2020

General Manager Sanofi Eurasia from October 1, 2018. Prior to that since January 1, 2016 worked as General Manager, Rx, Sanofi Russia & Belarus.  
 
Engineer by training with MBA degree from Cranfield School of Management, UK, Oxana has got more than nineteen years of in-depth knowledge and experience in pharmaceutical industry with a number of leadership roles in Marketing, Strategic Planning, and Sales in Russia and UK.  
 
Oxana started her career in pharmaceutical industry in 2001 with Eli Lilly UK. Over the following 13 years, she took on a number of senior management positions with increasing responsibility. In 2014, Oxana joined Sanofi as a Head of Diabetes BU in Russia.  

Katerina began her career with Janssen in 2001, holding a number of positions in the Sales, Marketing and Market Access teams. She has been a member of the Russian board of directors since 2010 and was appointed Country Manager Russia in 2015, and then she was promoted to the position of Managing Director Russia & CIS in 2017. In April 2019 Katerina was appointed CEO of Johnson & Johnson Russia & CIS.

Throughout her 17-year career with Janssen, Katerina has consistently demonstrated high standards of quality and strong results. She led the launch of a whole range of new products and work across a number of therapeutic areas, as well as establishing several new business units. In her role as Commercial Operations Director, Russia, Katerina successfully led commercial teams in close collaboration with other departments, which yielded great business results and drove the company’s overall success.

Katerina graduated with distinction from the International University in Moscow, where she studied law. She also completed specialist education for senior executives at the London School of Economics and Political Science and Moscow School of Management Skolkovo.

Inna Bakumenko joined Abbott as the General Manager in November 2019. The key priorities in this role are strategic portfolio development, digital transformation, and scaling up of management expertise to the country cluster. Inna has over 20 years of professional experience in the pharmaceutical industry in Russia and CIS. Prior to joining Abbott, Inna was in charge of Pfizer GEP in Russia and General Manager of Pfizer Upjoin in Russia. Early in her career, Inna worked as a medical representative of Janssen-Cilag, Johnson & Johnson’s division. Then she took various roles in sales and marketing and was in charge of business units of Servier, Allergan and Pfizer in Ukraine. From 2015 Inna was the General Manager of Pfizer in Ukraine and a regional head of GEP business in Ukraine, Caucasus and Central Asia. Inna received higher medical degree at Kharkov National Medical University and master's in marketing and management at the National Economical University by European program TACIS, and Harvard Business School.

Elena is recognized expert and leader of the Russian pharmaceutical industry, has 25 years of experience in leading international pharmaceutical companies, one of 25 women CEO of Russia according to RBC. 
 
2019 till present – President of the company Takeda Pharmaceuticals Russia 
2014-2019 General Manager, Abbott Russia 
2011-2014 General Manager, Meda Pharmaceuticals 
1995-2011 kept different positions in sales and marketing in such pharmaceutical companies as Pliva (Croatia), Novartis Pharma (Switzerland), Sanofi (France). 
1990-1993 graduated from the Oncology Institute of Russian Academy of Sciences., PhD. 
1987 graduated from the Moscow Medical Academy n.a. Sechenov, Department of General Medicine.

Adlane graduated in Marketing and Management from Lyon Business School and holds a Master’s Degree in International Trade from Lyon University.

Adlane Soudani joined Ipsen in France in 2005. He developed a specific expertise in the export business in several regions of the globe until he was promoted to Export Director for Latin America.

Building on his success in this role, in 2013 he was appointed General Manager, Ipsen in Algeria. In this position, he has been instrumental in building a strong team and leading it to reach record market shares for both the Specialty Care and Consumer Healthcare businesses.

Demonstrating a lot of resilience in a challenging market like Russia, Adlane successfully led the creation of a Joint-Venture in the country which has paved the way for building the first oncology factory in the Algeria. 

In October 2018 Adlane was appointed a General Manager of Ipsen in Russia & CIS.

Since then the company has started its fantastic transformation journey. Within a relatively short period of time Adlane managed to develop new capabilities within the company to be more focused on innovation and breakthrough solutions in oncology and rare diseases.  Thanks to the recently launched innovative breakthrough solution for kidney cancer treatment and other product yet to come for patients` unmet needs, Ipsen is transforming into one of the key players in oncology and orphan disease markets in Russia.

Adlane`s key focus in patient centricity and development of business in a compliant manner helped to bring innovation for the development of the company which can contribute to the development of the healthcare industry in Russia.

Graduated from the Geography Department of Kazan Federal University. Received an MBA at the Management School of Lancaster University (UK). Has over 20 years of experience in senior managerial positions in the pharmaceutical industry.

In 2011 won the “Manager of the Year” as per Platinum Ounce award, a prominent professional award in the Russian pharmaceutical field. In 2015, became the Head of the Eurasia business unit — encompassing Russia, the CIS states, Georgia and the Ukraine — in a pharmaceutical company Bosnalijek (Bosnia and Herzegovina), one of the largest pharmaceutical manufacturers in the Balkan States and Eastern Europe. Recently, the business unit led by Valentina has increased its influence by entering the markets of Kazakhstan, Belarus and Azerbaijan.

In 2017, Bosnalijek, with its production sites in Sarajevo, became one of the first companies that had its application approved by the Russian Ministry of Industry and Trade and received a GMP certificate. The Russian market is vital to Bosnalijek’s future; it is the second year in a row that Bosnalijek sales continue to grow at a double-digit rate, which is significantly faster than the market. Bosnalijek best sellers are LYSOBACT and ENTEROFURYL, ranking among Top 3 in their categories.

In 1988 graduated from the Chelyabinsk State Medical Institute with a specialization in «General Medicine».
In 1998 completed postgraduate studies and defended a thesis on «anesthesiology-resuscitation» and «oncology» in the P.A. Herzen Moscow Oncology Research Institute.
Worked as a practitioner in various medical institutions of the RF, held senior positions in the Ministry of Health of the RF, in the Ministry of Health of Moscow Region and in leading pharmaceutical companies: MEDSI Group of Companies, Pharmeco LLC, Biotec LLC.
Since April 2018 has taken up the position of CEO of PJSC «Pharmacy Chain 36.6»
In 2002 and 2006 the Ministry of Health of Moscow Region gave Mr. Nesterenko a commendation for his diligent work.